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Objective: To study the protective effect of telmisartan on rats with renal failure and its
mechanism.
Methods: 60 Wistar rats were chosen as study objective, and were divided into 4 groups
randomly: 15 in group A (sham operation group), 15 in group B (model group), 15 in
group C (telmisartan group) and 15 in group D (telmisartan + GW9962 group). The
difference of survival rate, blood-urine biochemical indexes, renal pathological change,
and the expression level of PPARg and nNOS were compared.
Results: After 12 weeks, the survival rate of group A was 93.33% (14/15), that of group
B was 46.67% (7/15), that of group C was 86.67% (13/15), that of group D was 60.00%
(9/15), and the difference among 4 groups had statistical signiﬁcance (P < 0.05). After 1
week, the difference of Scr, that of BUN and that of 24 h protein urine among 4 groups
was not statistical signiﬁcant (P > 0.05); after 3 weeks, 6 weeks and 12 weeks, these
difference was statistical signiﬁcant (P < 0.05). The difference of blood-urine
biochemical indexes, that of renal pathological change, and that of the expression level
of PPARg and nNOS was statistical signiﬁcant (P < 0.05).
Conclusions: Telmisartan has protective effect on renal failure caused by 5/6 nephrec-
tomy, which might be relative to the expression level of PPARg and nNOS.1. Introduction
Renal failure refers to partial or complete loss of kidney
function which is induced by renal disease or injury developing
to the ﬁnal stage, including acute renal failure and chronic renal
failure. Renal failure has the characteristics of high death and
disability. The patient's life mainly relies on dialysis which is
costly [1,2]. It is found that part of angiotensin receptor blockers
have a protective effect on kidney, among which telmisartan as
part of the activator of peroxisome proliferator activated
receptors g plays a dual role of interdicting AR and activating
PPARg [3,4]. In the present study, we aimed to explore the
protective effect of telmisartan on rats with renal failure and
its mechanism.2. Materials and methods
2.1. Experimental animals and groups
A total of 60 healthy male Wistar rats weighting 200–220 g
[average weight (210.4 ± 6.2) g] were chosen as study objective.
Rats were provided by Laboratory Animal Center of Tianjin
Medical University (certiﬁcate of approval no. 14-0812). 60 rats
were randomly divided into four groups: group A (sham oper-
ation group), group B (model group), group C (telmisartan
group) and group D (telmisartan + GW9962 group) with 15 rats
in each group.
2.2. Drugs and reagents
2.2.1. Drugs
Telmisartan (Yichang Changjiang Pharmaceutical Co., Ltd,
approval no. 20140105) was diluted to the solutions of 0.5 mg/
mL and 1 mg/mL with normal saline. GW9662 (Selleck
Chemicals, USA, purity > 99.00%) was diluted to the solution
of 1 mg/ml with normal saline.open access article under the CC BY-NC-ND
Figure 1. Survivorship curve of each group (%).
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Rabbit anti-rat PPAR gamma antibodies and nNOS anti-
bodies (primary antibodies) were provided by Santa Cruz
Biotechnology, Inc. HRP goat anti-rat IgG (secondary anti-
bodies) was provided by Shanghai Xueman Bio-Tech Co., Ltd.
Other reagents were provided by Beijing Cell Chip Biotech-
nology Co. Ltd.
2.3. Experimental method
2.3.1. Model establishment and administration
All the rats were fed 7 days to adapt the environment. 5/6
nephrectomy was performed in rats of group B and D to
establish renal failure model. After anesthetization by intraper-
itoneal injection of 2% pentobarbital sodium (40 mg/kg), rats
were ﬁxed on the operating table with prone position, then
suitable operating ﬁeld was selected for skin preparation. After
disinfection, skin was cut along the bilateral costalspinal angle.
The subcutaneous tissue and muscle were separated and renal
capsule was decorticated. Bilateral renal arteriovenous and
ureter were ligatured and the right kidney was completely
removed. After ligation of higher and lower part of the kidney,
1/3 kidney was cut and left side ligature was loosened. Renal
capsule of rats in sham operation group was decorticated without
resection of kidney.
In group C, 2 mL telmisartan solution (0.5 mg/mL) was used
for gavage once a day at 10: 00 am. Rats in group D were given
1 mL telmisartan (1 mg/mL) and 1 mL GW9662 solution (1 mg/
mL) to mix gavage once a day. Rats in groups A and B were
given with 2 mL normal saline for gavage once a day for 12
weeks.
2.3.2. Detection of blood and urine biochemical
indicator
Fasting tail venous bloods of all rats were obtained and 24-h
urine specimens were collected in metabolic cages. SCr, BUN
and 24-h proteinuria were detected. The above indexes should
be examined in all the feeding rats in 1, 3, 6 and 12 weeks.
Meanwhile, the survival rate in each group was recorded at the
end of each weekend.
2.3.3. Pathological change of glomerulus
After 12 weeks, all the survival rats were killed by cervical
dislocation. The residual kidney tissues of rats were picked with
prone position, among which 2/3 were washed with PBS buffer
solution to pale and ﬁxed with 10% neutral formalin to prepare
for parafﬁn imbedding. Injury degree of rat kidney tissue was
observed under light microscope by Periodic acid-Schiff stain.
Raji cell assay was used to calculate the CSI of glomerulus. Part
of sections were stained with MASSON and tubule interstitial
score (TIS) was evaluated under light microscope.
2.3.4. Detection of PPARg and nNOS expressions by
western blot
Part of renal tissues were cut into pieces and digested with
0.5% pancreatin to prepare single-cell suspension. Then the
single-cell suspension was centrifuged at 1 000 r/min for 5 min
and washed with PBS, and after lyse cells, total protein was
obtained. After protein quantiﬁcation, SDS-PAGE electropho-
resis, transferred to a membrane, sealed, and cut, rabbit anti-rat
PPAR gamma and b-actin antibodies were added for incubationat 4 C overnight. After washing, HRP goat anti-rat IgG (sec-
ondary antibody) was added for incubation at room temperature
for 1.5 h, and then the membrane was washed. ECL kit was used
for exposure and development. Detection of nNOS was same as
PPARg.
2.4. Statistical analysis
Data were analyzed with SPSS15.0 statistical software.
Measurement data were expressed as mean ± sd. One-way
analysis of variance was used for the analysis of comparison
among groups. The blood and urine biochemical indicator of rats
at different time was analyzed with repeated measures analysis
of variance, and measurement data were compared with c2 test.
P < 0.05 was considered as signiﬁcantly different.
3. Results
3.1. Survivorship curve of each group
After 12 weeks, survival rate in group A was 93.33% (14/15),
group B 46.67% (7/15), group C 86.67% (13/15), and group D
60.00% (9/15). The difference was statistically signiﬁcant
(P < 0.05) (Figure 1).
3.2. Blood and urine biochemical indicator in each
group
Before operation and after 1 week, SCr, BUN and 24-h
proteinuria of each group had no statistical difference
(P > 0.05), while after 3, 6 and 12 weeks, SCr, BUN and 24-h
proteinuria had statistical difference (P < 0.05). SCr, BUN and
24-h proteinuria of groups B, C and D in 3, 6 and 12 weeks had
statistical signiﬁcant difference (P < 0.05) compared with that
before operation (Table 1).
3.3. Histopathological change of rat renal tissue in each
group
The glomerulus and renal tubules in rats of group A were
roughly normal with occasional thickening of glomerular and
renal tubules basement membrane. Lesion of glomerulus and
renal tubules in rats of group B were obvious with clear in-
ﬂammatory cells inﬁltration and physaliphore. Lesions of
glomerular in groups C and D were ligher, and expansion and
edema could be seen in renal tubules. The lesion degree of group
C was less than that in group D. CIS and TIS in each group had
statistical signiﬁcant difference (P < 0.05) (Figure 2, Table 2).
Figure 2. Histopathology of kidney in each group.
Table 2
CIS and TIS of each group (mean ± sd).
Groups CSI TIS
A Group 3.44 ± 0.97 0.25 ± 0.11
B Group 21.82 ± 4.75 2.57 ± 0.81
C Group 9.76 ± 1.25 0.77 ± 0.23
D Group 14.53 ± 3.23 1.76 ± 0.54
F 8.097 6.343
P <0.05 <0.05
Figure 3. Expression of PPARg and nNOS in each group.
Table 3
Expression of PPARg and nNOS in each group (mean ± sd).
Groups PPARg nNOS
A Group 0.86 ± 0.17 0.91 ± 0.19
B Group 0.37 ± 0.09 0.41 ± 0.08
C Group 0.62 ± 0.12 0.65 ± 0.13
D Group 0.41 ± 0.10 0.45 ± 0.11
F 4.231 4.985
P <0.05 <0.05
Table 1
Blood and urine biochemical indicator in each group (mean ± sd).
Time Group Blood and urine biochemical indicator
SCr
(umol/L)
BUN
(mmol/L)
24-h Proteinuria
(mg)
Before
operation
A Group 32.5 ± 6.4 9.4 ± 1.3 27.8 ± 3.9
B Group 33.9 ± 6.3 9.1 ± 1.2 27.5 ± 4.1
C Group 32.7 ± 6.5 9.3 ± 1.4 27.6 ± 3.8
D Group 32.1 ± 6.6 9.5 ± 1.5 27.7 ± 3.7
1 w A Group 32.8 ± 6.1 9.5 ± 1.1 28.0 ± 3.5
B Group 36.8 ± 6.9 11.3 ± 1.5 30.4 ± 4.0
C Group 32.9 ± 6.4 9.6 ± 1.3 28.4 ± 3.9
D Group 33.9 ± 6.5 10.4 ± 1.7 28.7 ± 3.8
3 w A Group 33.1 ± 5.5 9.7 ± 1.4 28.1 ± 3.8
B Group 59.5 ± 11.8a 17.2 ± 2.1a 32.4 ± 5.9a
C Group 37.8 ± 5.9a 11.7 ± 1.1a 29.1 ± 4.3a
D Group 42.6 ± 6.8a 14.8 ± 1.9a 29.5 ± 4.1a
6 w A Group 34.3 ± 5.9 10.1 ± 1.5 28.6 ± 4.0
B Group 95.8 ± 14.7a 26.5 ± 2.9a 45.2 ± 9.1a
C Group 44.9 ± 7.8a 14.5 ± 2.0a 33.1 ± 4.9a
D Group 54.7 ± 9.5a 16.2 ± 2.3a 37.4 ± 6.2a
12 w A Group 35.6 ± 7.6 10.5 ± 1.7 29.5 ± 4.2
B Group 101.7 ± 15.8a 27.8 ± 3.1a 46.9 ± 9.8a
C Group 47.8 ± 8.2a 15.1 ± 2.2a 35.4 ± 5.1a
D Group 58.6 ± 10.7a 18.9 ± 2.5a 40.3 ± 6.9a
a Compared with that before operation.
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group
Expression levels of PPARg and nNOS in each group had
statistical difference (P < 0.05) (Figure 3, Table 3).4. Discussion
Telmisartan, belonging to ARB drugs, can control blood
pressure through inhibiting renin-angiotensin-aldosterone sys-
tem, which is widely used in the treatment of hypertension [5]. It
is found that the structure of telmisartan has differences with
other ARB drugs, and it has the activity of PPARg agonist [6].
PPARg has extensive biological function and is closely
associated with the process of glucolipid metabolism of body,
formation of atherosclerotic plaque and the proliferation of
vascular smooth muscle, meanwhile, PPARg plays a role in
the progress of glomerulus and renal tubules lesions [7,8].
Moreover, the decrease of expressions of nNOS in renal
cortex has a certain correlation with renal injury [9]. In the
present study, we established the model of renal failure in rats
by 5/6 nephrectomy and studied the protective effect of
telmisartan on kidney and the correlation of PPARg and Nnos.
Renal failure refers to partial or complete loss of kidney
function which is induced by renal disease or injury developing
to the ﬁnal stage. Normal kidney has certain compensatory
ability, while after 5/6 nephrectomy, kidney function is rapidly
declined and presents the state of decompensation. Therefore, 5/
6 nephrectomy can used to establish model of renal failure in
rats [10]. Rats in each group were performed different operations
and given different drugs. After 12 weeks, survival rate of rats in
sham operation group was 93.33% (14/15), and rats were unable
to tolerate the procedure and died in the operation. Survival rate
of rats in model group was 46.67% (7/15), and the cause of
death included unable to tolerate the procedure, infection and
severe arrhythmia induced by hyperkalemia. Survival rate of
rats in telmisartan group was 86.67% (13/15) and rats died of
postoperative infection. Survival rate of rats in
telmisartan + GW9962 group was 60.00% (9/15) and the
cause of death was the same as the model group rats, and the
difference was statistically signiﬁcant. In the detection of
blood and urine biochemical indicator in each group, SCr,
BUN and 24-h proteinuria of 3, 6 and 12 weeks had statistical
differences. Blood and urine biochemical indicator of 3, 6 and
12 weeks in rats with nephrectomy were signiﬁcantly
decreased compared with that before operation. During the
observation of histopathological change of rat renal tissue in
each group, the glomerulus and renal tubules in rats of sham
operation group were roughly normal with occasional
thickening of glomerular and renal tubules basement
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model group were obvious with clear inﬂammatory cells
inﬁltration and physaliphore. Lesions of glomerular in
telmisartan and telmisartan + GW9962 groups were ligher,
and expansion and edema could be seen in renal tubules. The
lesion degree of telmisartan group was less than that in
telmisartan + GW9962 group. The study showed that after 5/6
nephrectomy, renal injury and renal function of the rats were
obviously decreased, and telmisartan could play the protective
effect on kidney. When selective PPARg antagonist GW9662
was combined with telmisartan, the effect of telmisartan
declined, thus showing that the protective effect of telmisartan
on kidney is independent of RAAS, and is related to PPARg
[11,12].
It was found that the expression levels of PPARg and nNOS
in rats with nephrectomy were signiﬁcantly decreased compared
with that in sham operation group, while the expression levels in
telmisartan group were higher than other two groups. It showed
that when renal failure occurred, the expression levels of PPARg
and nNOS in rats were decreased, and telmisartan played a
protective role in kidney by up-regulating the expression levels
of PPARg and nNOS.
Results showed that the biological activity of PPARg is
wider and can involve in the processes including glucolipid
metabolism of the body, inﬂammatory response, immunologic
process and the regulation of cell cycle and apoptosis [13]. It was
reported that PPARg can inhibit glomerular sclerosis, renal
interstitial inﬂammatory cell inﬁltration and ﬁbrosis through
lowering the expression of genes in glomerular, such as PAI,
TGF and Type IV collagen, thus relieving renal lesion [14].
Nitric oxide is closely related to the function of glomerular,
including expanding afferent glomerular arteriole, regulating
haemodynamics, maintaining blood perfusion of the kidney,
balancing the feedback effect of glomerular and renal tubules,
inhibiting water and sodium reabsorption, and regulating
autonomic nerve activity of glomerulus [15,16]. nNOS
expression level has obvious relevance with chronic kidney
disease progression and the occurrence of kidney failure. The
decrease of nNOS in renal cortex is related to the progress of
decline in renal function, thickening of glomerular basement
membrane and glomerular sclerosis [17].
In conclusion, telmisartan has protective effect on renal
failure induced by 5/6 nephrectomy, which may be related to the
expression level of PPARg and nNOS.
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